IMDX
Q4 2026 EPS Estimate
$-0.23
Nov 9, 2026 · Reports after close
Revenue Estimate
$215,120

Analyst Sentiment

Wall St. Consensus
Buy
10 analysts·Moderate coverage
68
Score
7 Buy (70%)3 Hold (30%)0 Sell (0%)
Rating Breakdown
Strong Buy
00%
Buy
770%
Hold
330%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$8.00
+104.1%
Consensus
$9.50
+142.3%
Bull
$12.00
+206.1%
12-Month Target Range10 analysts
$8.00$9.50$12.00
Current $3.92Consensus
Current Price
$3.92
Upside to Consensus
$5.58

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev+659.70%
EPS
FY2028
Rev+304.83%
EPS
Raw consensus estimates (low / average / high) from covering analysts.
Annual
MetricFY2026EFY2027EFY2028E
Revenue Avg$882,800$7M$27M
Low$367,833$1M$25M
High$2M$12M$29M
EBITDA Avg$-26M$-23M$-16M
Low$-26M$-25M$-19M
High$-26M$-22M$-8M
EBIT Avg$-28M$-26M$-22M
Low$-28M$-27M$-24M
High$-28M$-24M$-13M
Net Income Avg$-28M$-26M$-22M
Low$-28M$-27M$-24M
High$-28M$-25M$-13M
EPS Avg$-0.91$-0.85$-0.62
Low$-0.92$-0.89$-0.80
High$-0.91$-0.80$-0.44
Analysts (Rev / EPS)5 / 35 / 32 / 2
Quarterly
MetricQ3 2026Q4 2026Q1 2027Q2 2027Q3 2027Q4 2027Q1 2028Q2 2028
Revenue Avg$215,120$447,280$303,700$785,450$1M$3M$4M$5M
Low$118,654$94,418$119,376$308,740$580,472$1M$2M$2M
High$371,783$1M$608,820$2M$3M$5M$8M$10M
EBITDA Avg$-8M$-8M$-8M$-7M$-7M$-6M$-5M$-4M
Low$-19M$-9M$-19M$-18M$-17M$-15M$-12M$-10M
High$-1M$-7M$-1M$-1M$-984,376$-784,099$-376,269$-97,043
EBIT Avg$-9M$-8M$-9M$-8M$-8M$-7M$-5M$-5M
Low$-20M$-9M$-20M$-19M$-18M$-16M$-13M$-11M
High$-2M$-8M$-2M$-2M$-2M$-1M$-1M$-985,034
Net Income Avg$-9M$-8M$-9M$-8M$-8M$-7M$-6M$-5M
Low$-20M$-9M$-20M$-19M$-18M$-16M$-13M$-11M
High$-2M$-8M$-2M$-2M$-2M$-1M$-1M$-1M
EPS Avg$-0.23$-0.23$-0.24$-0.22$-0.21$-0.19$-0.15$-0.13
Low$-0.54$-0.25$-0.55$-0.51$-0.48$-0.44$-0.35$-0.30
High$-0.05$-0.21$-0.05$-0.05$-0.04$-0.04$-0.03$-0.03
Analysts (Rev / EPS)4 / 15 / 24 / 14 / 14 / 14 / 13 / 13 / 1

Earnings Surprises

Recent Analyst Actions

Feb 17, 2026Lake Street
Insight Molecular Diagnostics price target raised to $12 from $8 at Lake Street
Target:$12.00
+125.1%from $5.33
Nov 11, 2025Needham
Insight Molecular Diagnostics Inc. (IMDX) PT Raised to $9 at Needham
Target:$9.00
+32.4%from $6.80
May 21, 2025UBS
OncoCyte price target raised to $8 from $5 at Lake Street
Target:$8.00
+160.6%from $3.07
Apr 24, 2024Needham
OncoCyte Corp (OCX) PT Raised to $4.25 at Needham
Target:$4.25
+78.6%from $2.38
Dec 1, 2022Lake Street
Lake Street Downgrades OncoCyte to Hold, Lowers Price Target to $0.5
Target:$0.50
-94.7%from $9.44
Nov 18, 2022Piper Sandler
Piper Sandler Downgrades OncoCyte to Neutral, Lowers Price Target to $0.5
Target:$0.50
-94.1%from $8.52
Aug 17, 2022Piper Sandler
OncoCyte price target raised to $1.50 from $1.40 at Piper Sandler
Target:$1.50
-91.4%from $17.48
Aug 11, 2022Lake Street
Lake Street Maintains Buy on OncoCyte, Lowers Price Target to $3
Target:$3.00
-84.4%from $19.27
Aug 11, 2022Needham
Needham Maintains Buy on OncoCyte, Lowers Price Target to $2.1
Target:$2.10
-89.0%from $19.02
May 15, 2022Piper Sandler
OncoCyte price target lowered to $1.40 from $1.80 at Piper Sandler
Target:$1.40
-93.8%from $22.60
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.